OBJECTIVETo clarify expression and subcellular localization of XIAP and XAF1 protein in human normal oral keratinocytes (hNOK) and Tca8113 cells human tongue carcinoma cell line.

METHODSThe hNOKs and Tca8113 cells were cultured in vitro. Expression and subcellular localization of XIAP and XAF1 protein were examined by combination of indirect immunofluorescence and confocal laser scanning microscopy.

RESULTSXIAP expression was weak in the hNOKs and fluorescence staining localized chiefly in the cytoplasm and perinuclear areas. In the Tca8113 cells, high level of XIAP protein could be detected in both the cytoplasm and the nucleus. In the hNOKs, XAF1 distributed mostly in the nucleus. Homogeneous nuclear and cytoplasmic distribution of XAF1 could be visualized in the Tca8113 cells.

CONCLUSIONSIn cancerization of oral mucosa, XIAP protein could play an important antiapoptotic role by overexpression, while XAF1 protein does not appear to antagonize effectively the role of XIAP.

Apoptosis ; Cell Line, Tumor ; Cells, Cultured ; Humans ; Intracellular Signaling Peptides and Proteins ; Keratinocytes ; metabolism ; pathology ; Mouth Mucosa ; cytology ; metabolism ; Neoplasm Proteins ; metabolism ; Tongue Neoplasms ; metabolism ; pathology ; X-Linked Inhibitor of Apoptosis Protein ; metabolism

OBJECTIVESTo investigate the possibilities of an association between the degrees of HBV suppression with nucleoside treatments at week 24 and week 52 in hepatitis B patients and to find a useful predictor for treatment efficacy.

METHODSIn this phase III, double-blind, multicenter trial, we compared the efficacy of telbivudine treatment with lamivudine treatment in 332 Chinese compensated chronic hepatitis B patients. The patients were randomly assigned to a daily 600 mg telbivudine treatment group or daily 100 mg lamivudine group for 24 weeks. They were then categorized into 4 groups according to their serum HBV DNA levels (copies/ml) at week 24: a PCR-undetectable group (< 300 copies/ml); a QL- < 10(3) copies/ml group; a 10(3)-<10(4) copies/ml group; and a > or = 10(4) copies/ml group. The treatments were continued as they previously had been for another 28 weeks and the patients serum HBV DNA levels were examined again.

RESULTSAt week 52, mean reductions of serum HBV DNA were significantly greater in the telbivudine-treated patients than in the lamivudine-treated group (6.2 log10 vs 5.4 log10, t = 3.6, P < 0.01). Viral resistance was twice as common in lamivudine-treated patients compared to those receiving telbivudine. Telbivudine was well-tolerated with an adverse event profile similar to that of lamivudine. The lower the HBV DNA level achieved at week 24, the higher HBV DNA non-detectable by PCR. ALT normalization and HBeAg seroconversion achieved at week 52, and viral resistance at week 48 decreased parallel to the degree of HBV DNA inhibition.

CONCLUSIONHBV DNA PCR-undetectable at week 24 in nucleoside-treated hepatitis B patients suggests a better efficacy at week 52 and lower viral resistance at week 48. The degree of suppression of HBV at week 24 may be used as a predictor of 1-year outcome.

Adolescent ; Adult ; Aged ; Antiviral Agents ; therapeutic use ; DNA, Viral ; blood ; Double-Blind Method ; Female ; Hepatitis B, Chronic ; drug therapy ; Humans ; Lamivudine ; therapeutic use ; Male ; Middle Aged ; Nucleosides ; therapeutic use ; Pyrimidinones ; therapeutic use ; Thymidine ; analogs & derivatives ; Treatment Outcome ; Young Adult